Qardio releases chest-mounted continuous ECG monitor

Qardio has released a wearable electrocardiogram (ECG) monitor for pre-order. The QardioCore is attached around the chest, requires no wires and is able to send information directly into a user’s phone for easy access of data.

QardioCore collects patient data through 20 million data points and transmits it in real-time to a smartphone application. The monitor analyzes the electrical changes in the skin from the heart's electrophysiological activity and converts this information into a continuous ECG. The monitor also measures heart rate, heart rate variability, respiratory rate, temperature and activity data.

"The ability to view and analyze such important data remotely and in context, as it is being generated, can substantially enhance the diagnostic yield. QardioCore is a game-changer for doctors, patients and health conscious individuals, and a big step towards preventative health," said Rosario Iannella, CTO at Qardio. "For elite athletes, cardiovascular health is the cornerstone of performance, and QardioCore puts a wealth of actionable biometrics including medical-grade beat-by-beat heart tracking into an athlete's hands, empowering them to be their best."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup